2005
DOI: 10.1158/0008-5472.can-04-4146
|View full text |Cite
|
Sign up to set email alerts
|

T25 Repeat in the 3′ Untranslated Region of the CASP2 Gene: A Sensitive and Specific Marker for Microsatellite Instability in Colorectal Cancer

Abstract: DNA mismatch repair deficiency is observed in about 10% to 15% of all colorectal carcinomas and in up to 90% of hereditary nonpolyposis colorectal cancer (HNPCC) patients. Tumors with mismatch repair defects acquire mutations in short repetitive DNA sequences, a phenomenon termed high-level microsatellite instability (MSI-H). The diagnosis of MSI-H in colon cancer is of increasing relevance, because MSI-H is an independent prognostic factor in colorectal cancer, seems to influence the efficacy of adjuvant chem… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
102
0

Year Published

2006
2006
2022
2022

Publication Types

Select...
9

Relationship

5
4

Authors

Journals

citations
Cited by 130 publications
(109 citation statements)
references
References 20 publications
4
102
0
Order By: Relevance
“…MSI analysis was performed using the standard NCI/ICG-hereditary nonpolyposis colorectal cancer marker panel 27 and CAT25. 28 PCR products were separated on an ABI3700 automated sequencer (Applied Biosystems, Warrington, UK). Tumors were classified as MSI-H if at least two of the markers displayed a shift in product length compared with the product of non-neoplastic mucosa.…”
Section: Msi Analysismentioning
confidence: 99%
“…MSI analysis was performed using the standard NCI/ICG-hereditary nonpolyposis colorectal cancer marker panel 27 and CAT25. 28 PCR products were separated on an ABI3700 automated sequencer (Applied Biosystems, Warrington, UK). Tumors were classified as MSI-H if at least two of the markers displayed a shift in product length compared with the product of non-neoplastic mucosa.…”
Section: Msi Analysismentioning
confidence: 99%
“…Tumours were typed for MSI using the standard NCI/ ICG-HNPCC marker panel (Boland et al, 1998) and CAT25 as described earlier (Findeisen et al, 2005). For tumour staging, the UICC/AJCC TNM system was applied (American Joint Committee on Cancer, 1997).…”
Section: Tumour Samples and Msi Analysismentioning
confidence: 99%
“…PCR primers for the amplification of these markers were described elsewhere. 15,16 The sense primers were chemically labeled at the 5Ј end with 5-carboxyfluorescein fluorescent dyes. PCR was performed in a total volume of 25 l using a final concentration of 200 mol/L deoxyribonucleotide triphosphates (MBI Fermentas, St. Leon-Rot, Germany), 500 nmol/L each sense and antisense primer (Eurogentec, Seraing, Belgium), 1X PCR buffer (60 mmol/L Tris-SO 4 , pH 8.9; 18 mmol/L (NH 4 )SO 4 ; 2 mmol/L MgSO 4 ) and 1 unit of Discoverase denaturing high performance liquid chromatography DNA polymerase (Invitrogen, Merelbeke, Belgium).…”
Section: Mononucleotide Marker Assaymentioning
confidence: 99%
“…Four of these mononucleotide repeats (PTHL3, SEC63, HPDMPK, and U79260) showed mutation rates in 80% or more of MSI-H CRCs and were suggested as new candidate genes for diagnostic purposes. Similarly, Findeisen et al 16 described a novel T 25 mononucleotide marker in the 3Ј untranslated region of the CASP2 gene (CAT25) that displayed a quasimonomorphic repeat pattern in normal tissue and represented a highly promising candidate marker for future highthroughput MSI testing.…”
mentioning
confidence: 99%